瑞科生物-B(02179.HK)新冠疫苗ReCOV與mRNA疫苗比對研究獲菲律賓當局批准
瑞科生物-B(02179.HK)公布,公司已於近日就其重組蛋白新冠病毒疫苗ReCOV獲得菲律賓國家食品藥品監督管理局的臨床試驗批准,同意公司就ReCOV在18周歲或以上已接種兩劑滅活新冠疫苗基礎免疫的健康人群中,開展隨機、雙盲、陽性苗對照的II期臨床試驗,以評估ReCOV與輝瑞(PFE.US)mRNA疫苗COMIRNATY免疫原性和安全性方面的差異。公司擬於近期啟動臨床入組。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.